Welcome to our dedicated page for Atyr Pharma SEC filings (Ticker: ATYR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing aTyr Pharma’s filings can feel like running a clinical trial of your own. Each 10-K is packed with tRNA-synthetase science, efzofitimod study data, and detailed cash-runway tables that stretch past a hundred pages. Skimming for pivotal trial milestones or anti-NRP2 pipeline costs is a challenge even for seasoned biotech analysts.
Stock Titan resolves that complexity. Our AI turns the aTyr Pharma annual report 10-K simplified goal into reality, highlighting safety findings, R&D spending, and key risk-factor wording in minutes. Need the latest aTyr Pharma quarterly earnings report 10-Q filing? We post it the moment it hits EDGAR and attach an AI summary that flags burn-rate shifts and partnership revenue. Real-time alerts surface aTyr Pharma Form 4 insider transactions so you can monitor executive stock activity before crucial read-outs. We also translate every aTyr Pharma 8-K material events explained notice into clear language, whether it’s interim data, financing, or board changes.
Investors come here to answer everyday questions: “Where are the aTyr Pharma insider trading Form 4 transactions?”, “What does the aTyr Pharma proxy statement executive compensation reveal about incentive alignment?”, or “How do I start understanding aTyr Pharma SEC documents with AI?” Alongside full-text filings, you’ll find:
- AI-powered summaries that explain clinical endpoints and financial pivots
- Form 4 dashboards showing aTyr Pharma executive stock transactions Form 4 in real-time
- Side-by-side aTyr Pharma earnings report filing analysis for quarter-over-quarter trends
- Automatic email or SMS alerts the moment a new document posts
Skip the page-count marathon. Our platform delivers every detail—clearly, quickly, and without the biotech jargon.
aTyr Pharma (ATYR) reported Q3 2025 results showing continued investment in its pipeline and a larger loss as it advances efzofitimod. License and collaboration revenue was $190 thousand. Research and development expense rose to $22.1 million, and general and administrative expense was $4.8 million, leading to a net loss of $25.7 million (basic and diluted net loss per share $0.26).
Cash, cash equivalents and available-for-sale investments totaled $92.9 million as of September 30, 2025. Year-to-date, the company raised $66.4 million via its Jefferies at‑the‑market program, selling 13,887,177 shares at a weighted‑average price of $4.94. Operating cash use for the first nine months was $49.8 million. Shares outstanding were 97,986,634 as of September 30, 2025.
The company announced that the Phase 3 EFZO-FIT study in pulmonary sarcoidosis did not meet its primary endpoint, though nominal improvements were observed on certain symptom measures, and efzofitimod was generally well‑tolerated. Management plans to meet the FDA in the first quarter of 2026 to discuss a path forward. Two putative securities class action complaints were filed in October 2025; no liability has been recorded.
aTyr Pharma (ATYR) reported that it issued a press release announcing financial results for the quarter ended September 30, 2025. The company furnished the press release as Exhibit 99.1 to an Item 2.02 Form 8-K. The information under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act. The filing also lists Exhibit 104 for the cover page Inline XBRL data.
aTYR Pharma (ATYR) director Paul Schimmel reported purchases totaling 1,000,000 common shares across
Federated Hermes, Inc. and related reporting persons disclose beneficial ownership of 10,544,437 shares of aTyr Pharma, Inc. common stock, representing 10.76% of the class. The filing states the shares are held in the ordinary course of business and were not acquired to change or influence control. Ownership is reported across Federated Hermes, a Voting Shares Irrevocable Trust, and three individual reporting persons who each disclose shared voting and dispositive power over the same aggregate stake. The filing includes exhibits for reporting-person classification, a joint-filing agreement, and a power of attorney.
aTYR Pharma reported results from a 268-patient global Phase 3 study in pulmonary sarcoidosis comparing efzofitimod 3.0 mg/kg and 5.0 mg/kg versus placebo over 48 weeks with a protocol-guided steroid taper. The primary steroid-reduction endpoint showed mean daily oral corticosteroid (OCS) doses of 2.79 mg for 5.0 mg/kg efzofitimod versus 3.52 mg for placebo (p=0.3313), which was not statistically significant. Secondary measures showed a statistically significant improvement in KSQ-Lung score for 5.0 mg/kg (change 10.36 vs 6.19; p=0.0479) and a higher rate of complete steroid withdrawal with KSQ-Lung improvement (29.5% vs 14.4%; p=0.0199). Change in FVC was similar between groups (−1.81 vs −2.11; p=0.7875). Treatment was generally well tolerated at both doses.
FAQ
What is the current stock price of Atyr Pharma (ATYR)?
What is the market cap of Atyr Pharma (ATYR)?
